| ALECTOR INC. |
| USA |
| Gesundheit |
| US0144421072 / A2PCBM |
| 0Z2 (Frankfurt) / ALEC (NASDAQ) |
| FRA:0Z2, ETR:0Z2, 0Z2:GR, NASDAQ:ALEC |
| - |
| https://alector.com/ |
|
Alector Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to counteract the progression of neurodegenerative diseases such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. The company harnesse..
>Volltext.. |
| 192.75 Mio. EUR |
| 7.28 Mio. EUR |
| 18.2 Mio. EUR |
| -117.72 Mio. EUR |
| -123.58 Mio. EUR |
| -1.2 EUR |
| 31.33 Mio. EUR |
| 56.89 Mio. EUR |
| -159.12 Mio. EUR |
| 3.68 |
| -81.55% |
| -5.82% |
| - |
| - |
| - |
| ALECTOR |
| 01.04.26 |